Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inflammatory Basis of Pulmonary Arterial Hypertension: Implications for Perioperative and Critical Care Medicine.

Literature DB >> 31094755

Inflammatory Basis of Pulmonary Arterial Hypertension: Implications for Perioperative and Critical Care Medicine.

Neil M Goldenberg¹, Marlene Rabinovitch, Benjamin E Steinberg.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2019 PMID： 31094755 PMCID： PMC6768739 DOI： 10.1097/ALN.0000000000002740

Source DB: PubMed Journal: Anesthesiology ISSN： 0003-3022 Impact factor: 7.892

× No keyword cloud information.

71 in total

1. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.

Authors: Melanie P Chin; George L Bakris; Geoffrey A Block; Glenn M Chertow; Angie Goldsberry; Lesley A Inker; Hiddo J L Heerspink; Megan O'Grady; Pablo E Pergola; Christoph Wanner; David G Warnock; Colin J Meyer
Journal: Am J Nephrol Date: 2018-01-18 Impact factor: 3.754

2. Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245

3. Pulmonary arterial hypertension and the Enigma code of smouldering inflammation.

Authors: Jose Gomez-Arroyo; Antonio Abbate; Norbert F Voelkel
Journal: Eur Respir J Date: 2016-08 Impact factor: 16.671

4. Elafin Reverses Pulmonary Hypertension via Caveolin-1-Dependent Bone Morphogenetic Protein Signaling.

Authors: Nils P Nickel; Edda Spiekerkoetter; Mingxia Gu; Caiyun G Li; Hai Li; Mark Kaschwich; Isabel Diebold; Jan K Hennigs; Ki-Yoon Kim; Kazuya Miyagawa; Lingli Wang; Aiqin Cao; Silin Sa; Xinguo Jiang; Raymond W Stockstill; Mark R Nicolls; Roham T Zamanian; Richard D Bland; Marlene Rabinovitch
Journal: Am J Respir Crit Care Med Date: 2015-06-01 Impact factor: 21.405

5. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension.

Authors: Frédéric Perros; Peter Dorfmüller; David Montani; Hamida Hammad; Wim Waelput; Barbara Girerd; Nicolas Raymond; Olaf Mercier; Sacha Mussot; Sylvia Cohen-Kaminsky; Marc Humbert; Bart N Lambrecht
Journal: Am J Respir Crit Care Med Date: 2011-11-22 Impact factor: 21.405

6. Pulmonary hypertension: an important predictor of outcomes in patients undergoing non-cardiac surgery.

Authors: Roop Kaw; Vinay Pasupuleti; Abhishek Deshpande; Tarek Hamieh; Esteban Walker; Omar A Minai
Journal: Respir Med Date: 2010-12-31 Impact factor: 3.415

Review 7. Perioperative Inflammation and Its Modulation by Anesthetics.

Authors: Jan Rossaint; Alexander Zarbock
Journal: Anesth Analg Date: 2018-03 Impact factor: 5.108

8. Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality.

Authors: Gautam Ramakrishna; Juraj Sprung; Barugur S Ravi; Krishnaswamy Chandrasekaran; Michael D McGoon
Journal: J Am Coll Cardiol Date: 2005-05-17 Impact factor: 24.094

Review 9. Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors: Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal: BMJ Date: 2018-03-14

10. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension.

Authors: Edda Spiekerkoetter; Yon K Sung; Deepti Sudheendra; Matthew Bill; Micheala A Aldred; Mariëlle C van de Veerdonk; Anton Vonk Noordegraaf; Janel Long-Boyle; Rajesh Dash; Phillip C Yang; Allan Lawrie; Andrew J Swift; Marlene Rabinovitch; Roham T Zamanian
Journal: Am J Respir Crit Care Med Date: 2015-07-15 Impact factor: 21.405

12 in total

Review 1. Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension.

Authors: Nicholas E King; Evan Brittain
Journal: Pulm Circ Date: 2022-01-18 Impact factor: 2.886

2. Necrosis-Released HMGB1 (High Mobility Group Box 1) in the Progressive Pulmonary Arterial Hypertension Associated With Male Sex.

Authors: Marina Zemskova; Nolan McClain; Maki Niihori; Mathews V Varghese; Joel James; Ruslan Rafikov; Olga Rafikova
Journal: Hypertension Date: 2020-10-05 Impact factor: 10.190

Review 3. Inflammasome Activation in Pulmonary Arterial Hypertension.

Authors: Anna Foley; Benjamin E Steinberg; Neil M Goldenberg
Journal: Front Med (Lausanne) Date: 2022-01-13

Review 4. Bioactivities and mechanisms of natural medicines in the management of pulmonary arterial hypertension.

Authors: Zhijie Yu; Jun Xiao; Xiao Chen; Yi Ruan; Yang Chen; Xiaoyuan Zheng; Qiang Wang
Journal: Chin Med Date: 2022-01-15 Impact factor: 5.455

5. Identification of Crucial Hub Genes and Differential T Cell Infiltration in Idiopathic Pulmonary Arterial Hypertension Using Bioinformatics Strategies.

Authors: Xiaomei Yang; Cheng Wang; Yicheng Lin; Peng Zhang
Journal: Front Mol Biosci Date: 2022-01-20